Jiangxi Kerui Pharmaceutical Co. Ltd. has disclosed new prodrugs of fungal GPI-anchored wall transfer protein 1 (GWT1) inhibitors potentially useful for the treatment of fungal infections.
Changchun Genescience Pharmaceuticals Co. Ltd. has synthesized new molecular glue degraders comprising E3 ubiquitin-protein ligase-binding agents acting as proto-oncogene Vav (VAV1) degradation inducers. They are described as potentially useful for the treatment of ulcerative colitis, Crohn’s disease, rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus and myasthenia gravis.
Laekna Pharmaceutical Ningbo Co. Ltd. has disclosed Werner syndrome ATP-dependent helicase (WRN; RECQ3; RECQL2) inhibitors found to be potentially useful for the treatment of cancer.
Researchers from Ascentage Pharma Group Corp. Ltd. and Ascentage Pharma (Suzhou) Co. Ltd. have identified proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase (such as Von Hippel-Lindau disease tumor suppressor [VHL]) coupled to a Bcl-2-like protein 1 (Bcl-xl; Bcl-X; BCL2L1)-targeting moiety via a linker acting as Bcl-xl degradation inducers reported to be useful for the treatment of cancer.
Shanghai Yingli Pharmaceutical Co. Ltd. has discovered hydrazine-structured compounds as inhibitors of GTPase KRAS and its mutants. They are reported to be useful for the treatment of cancer.
Pharmgen Science Inc. has patented H+/K+-ATPase inhibitors that are potentially useful for the treatment of asthma, esophagitis, Helicobacter pylori infection, gastroesophageal reflux disease, gastritis, peptic ulcer and more.
RSS